Back to Authors

Abdullaev, Ziedulla

https://orcid.org/0000-0003-2960-0045

Mayo Clinic

National Institutes of Health

Citations 2

A novel out-of-frame CREBBP::TRAP1 fusion in malignant intracerebral nerve sheath tumor
Chakraborty, Debopriya, Donnelly, Liam, Lefferts, Joel A. , Green, Donald C, Shannon, Patrick M., Mm, Quezado, Abdullaev, Ziedulla , Aldape, Kenneth D, Lin, Chun‐Chieh , Shannon, Patrick M, Quezado, M.

Journal of Neuropathology & Experimental Neurology | December 30, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/jnen/nlaf162 Get It

Atypical Teratoid Rhabdoid Tumor of the Brain in a Young Adult With Down Syndrome: Case Report and Literature Review
Judd, Dallin, Almefty, Kaith K. , Vern-Gross, T.Z., Hoffman, Lindsey M. , Abdullaev, Ziedulla , Quezado, Martha , Aldape, Kenneth , Tiwari, Nishant , Vaughn, Jennifer, Mangum, Ross , Vern-Gross, Tamara Z, Mangum, Ross

Journal of Pediatric Hematology/Oncology | November 26, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/mph.0000000000002977 Get It

Atypical teratoid/rhabdoid tumor (ATRT) is an aggressive, malignant embryonal tumor with dismal long-term survival despite aggressive multimodal therapy. While this tumor typically presents in infancy or early childhood, there are published case reports of adult-onset ATRT. Making prognostic conclusions or therapeutic decisions for this older patient population remains challenging due to the paucity of these reports. A 25-year-old female with Down syndrome presented with dysphagia and facial droop and was found to have an avidly enhancing, cerebellopontine angle mass. Histology demonstrated sheets of rhabdoid cells with loss of INI1 expression, pathognomonic for ATRT. Further sequencing detected a frameshift SMARCB1 mutation and methylation profiling matched with high confidence to the MYC subclass of ATRT. The patient was treated with subtotal surgical resection and focal proton beam irradiation, followed by chemotherapy on a modified regimen due to concern for heightened risk of treatment-related toxicity. On most recent follow-up 22 months from diagnosis, the patient remains without evidence of disease. This report represents the first known case of ATRT in a young adult patient with Down syndrome, offering unique mechanistic insight into the tumorigenesis of ATRT. Further studies are needed to define an appropriate risk-adapted and standardized therapeutic approach for this patient population.